Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2006
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
C01EB18
|
| gptkbp:CASNumber |
111855-37-5
|
| gptkbp:contraindication |
liver cirrhosis
strong CYP3A inhibitors strong CYP3A inducers |
| gptkbp:drugClass |
antianginal agent
|
| gptkbp:eliminationHalfLife |
7 hours
|
| gptkbp:form |
extended-release tablet
|
| gptkbp:genericName |
ranolazine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ranexa
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Gilead_Sciences
|
| gptkbp:mechanismOfAction |
inhibits late phase of the inward sodium current
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation dizziness headache |
| gptkbp:synonym |
ranolazine
|
| gptkbp:usedFor |
chronic angina
|
| gptkbp:bfsParent |
gptkb:CVTX
gptkb:Ranolazine |
| gptkbp:bfsLayer |
7
|